qualiti
safeti
commerci
vaccin
profound
import
contrari
precaut
effort
use
biolog
materi
vaccin
develop
product
may
lead
potenti
contamin
vaccin
known
unknown
extran
agent
ea
veterinari
field
offici
list
ea
compil
legal
framework
describ
potenti
agent
must
test
manufactur
vaccin
nevertheless
detect
known
unknown
contamin
vaccin
common
duti
manufactur
author
veterinari
human
field
share
similar
need
special
technic
approach
stateofart
molecular
method
randomli
prime
pcr
combin
massiv
parallel
sequenc
mp
microarray
may
open
new
perspect
extran
agent
test
robust
efficaci
technic
approach
vaccin
control
clearli
demonstr
human
vaccin
exampl
porcin
circoviru
type
contamin
reveal
rotarix
human
rotaviru
vaccin
consequ
implic
review
herebi
veterinari
regulatori
point
view
benefit
vaccin
unquestion
vaccin
gener
one
effect
mean
prevent
infecti
diseas
anim
human
anniversari
celebr
smallpox
erad
recent
global
freedom
rinderpest
announc
food
agricultur
organis
unit
nation
fao
underlin
remark
achiev
vaccin
vaccin
veterinari
scienc
vaccin
help
protect
health
welfar
anim
prevent
spread
diseas
human
anim
diseas
respons
least
loss
product
reduct
loss
paramount
import
consid
fact
european
union
appli
preemptiv
cull
handl
outbreak
highli
contagi
socal
transboundari
anim
diseas
tad
cost
tad
outbreak
tremend
anim
health
measur
appli
destruct
carcass
compens
paid
farmer
estim
cost
uk
footandmouth
diseas
fmd
outbreak
approx
million
usd
million
avian
influenza
ai
outbreak
netherland
cost
least
usd
million
classic
swine
fever
csf
outbreak
netherland
caus
usd
billion
loss
whenev
possibl
vaccin
live
polici
follow
mass
slaughter
anim
outbreak
extrem
high
cost
also
reject
societi
ethic
basi
compar
high
cost
tad
outbreak
develop
brand
new
vaccin
need
approx
usd
million
nevertheless
whole
process
may
take
eight
ten
year
includ
demonstr
safeti
efficaci
new
product
viral
safeti
vaccin
key
issu
veterinari
human
vaccin
impli
assur
freedom
medicin
product
agent
state
label
furthermor
viral
safeti
regard
vaccin
also
mean
residu
pathogen
within
accept
limit
safe
use
inactiv
agent
complet
inactiv
viral
safeti
may
jeopardis
follow
main
factor
revers
virul
ii
recombin
iii
incomplet
inactiv
iv
contamin
ea
vaccin
develop
product
profoundli
link
use
biolog
materi
anim
human
origin
cell
cultur
obtain
variou
sourc
foetal
calf
serum
fc
use
grow
cell
use
biolog
materi
vaccin
develop
product
may
lead
potenti
contamin
vaccin
product
contamin
may
happen
variou
step
manufactur
procedur
includ
start
materi
master
work
seed
virus
product
procedur
form
finish
product
ensur
viral
safeti
anim
human
medicin
product
regul
guidelin
develop
moreov
offici
list
ea
compil
ph
eur
see
chapter
european
medicin
agenc
ema
describ
potenti
agent
must
test
manufactur
vaccin
methodolog
test
vaccin
detect
ea
similar
veterinari
human
field
recent
case
technic
background
reveal
human
vaccin
offer
sever
gener
implic
vaccin
control
ea
detect
discuss
review
herebi
veterinari
author
point
view
number
identifi
virus
reach
approxim
viral
speci
howev
like
number
virus
globe
may
exceed
base
anoth
calcul
number
could
even
strike
presum
everi
vertebr
anim
endem
virus
given
fact
vertebr
speci
obvious
found
highli
advis
screen
least
anim
come
contact
obtain
knowledg
virus
may
harbour
discuss
viral
divers
evolut
also
import
note
virus
evolv
regular
basi
constantli
fuell
mutat
lead
complex
mutant
distribut
term
viral
quasispeci
quasispeci
ensur
high
genet
flexibl
allow
rapid
adapt
environ
accordingli
vast
major
virus
still
belong
unknown
emerg
viru
categori
today
consid
viral
ea
three
categori
distinguish
known
known
agent
known
suspect
sampl
test
ii
known
unknown
agent
known
test
necessarili
suspect
sampl
iii
unknown
unknown
agent
yet
unknown
current
test
contrari
unequivoc
advantag
vaccin
vaccin
past
presenc
offer
sever
exampl
certain
vaccin
contamin
foami
viru
spumaretrovirida
identifi
contamin
primari
monkey
kidney
cultur
use
vaccin
product
earli
viru
caus
foamlik
syncyti
effect
cell
cultur
lead
cell
lysi
destruct
cell
cultur
howev
caus
clinic
symptom
vivo
infect
anim
induc
lifelong
persist
infect
shown
yellow
fever
live
attenu
vaccin
prepar
chicken
embryo
fibroblast
infect
avian
leukosi
viru
alv
nevertheless
increas
risk
cancer
observ
vaccin
individu
expect
consid
alv
grow
effici
mammalian
cell
caliciviru
found
chines
hamster
ovari
cho
cell
jorgensen
et
al
reveal
newcastl
diseas
viru
ndv
vaccin
strain
differ
live
poultri
vaccin
live
attenu
multicompon
canin
vaccin
contamin
serotyp
bluetongu
viru
caus
abort
death
pregnant
bitch
pestivirus
bvdv
type
one
common
ea
veterinari
human
vaccin
potenti
sourc
pestiviru
live
vaccin
prepar
human
veterinari
use
may
use
fc
appli
grow
cell
vaccin
product
threat
besid
bvdv
type
novel
bovin
pestivirus
bvdv
also
detect
foetal
calf
serum
use
diagnost
laboratori
bioindustri
batch
usual
origin
brazil
contamin
bovin
serum
sampl
came
thailand
diagnost
problem
pose
novel
bovin
pestivirus
primer
set
design
bvdv
usual
fail
detect
bvdv
sequenc
anoth
recent
ea
replicationcompet
felin
endogen
gretroviru
xenotrop
host
spectra
found
felin
parvoviru
vaccin
canin
distemp
adenoviru
type
parvoviru
type
vaccin
origin
use
endogen
retroviru
suscept
cell
line
instanc
crandellre
felin
kidney
crfk
cell
wide
appli
produc
dog
vaccin
especi
canin
coronaviru
parvoviru
notabl
case
human
vaccin
contamin
date
may
centuri
ten
million
peopl
worldwid
immunis
polio
vaccin
contain
simian
viru
found
caus
cancer
anim
associ
human
brain
bone
lung
cancer
howev
clear
connect
found
certain
vaccin
human
tumour
case
debat
consid
ea
handl
regulatori
point
view
reburden
recent
porcin
circoviru
found
rotaviru
vaccin
wide
use
worldwid
children
case
trigger
paramount
interest
scientif
regulatori
commun
also
posit
vaccin
vaccin
biosafeti
immens
public
attent
http
editioncnncom
rotarix
genet
engin
vaccin
prevent
diarrhoea
caus
rotaviru
infect
creat
glaxosmithklin
gsk
isol
human
rotaviru
strain
infect
child
cincinnati
use
african
green
monkey
kidney
cell
produc
origin
viral
seed
stock
rotarix
vaccin
made
licens
us
health
author
food
drug
administr
fda
besid
us
use
altogeth
countri
includ
eu
member
state
approxim
million
children
worldwid
primarili
latin
america
approx
million
unit
state
vaccin
rotarix
ea
circoviru
first
describ
tischer
et
al
contamin
porcin
kidney
cell
cultur
first
reveal
rotarix
academ
research
team
use
metagenom
microarray
test
aim
evalu
puriti
eight
live
viru
vaccin
polio
rubella
measl
yellow
fever
human
herp
varicella
chicken
pox
rotaviru
rotarix
rotateq
multival
measlesmumpsrubella
mmr
vaccin
fda
licens
process
rotarix
met
fda
standard
includ
demonstr
freedom
transmiss
spongiform
encephalopathi
tse
certain
bovin
virus
bovin
serum
use
prepar
origin
viral
seed
stock
porcin
trypsin
also
use
produc
viral
seed
stock
gsk
confirm
presenc
cell
bank
seed
vaccin
deriv
suggest
presenc
earli
stage
vaccin
develop
concord
fact
consid
harmless
human
even
caus
diseas
natur
host
swine
unexpect
pattern
seriou
advers
reaction
rotarix
report
countri
nevertheless
subsequ
fda
learn
contamin
doctor
advis
use
vaccin
time
public
health
offici
emphasis
suspens
rotarix
usag
appli
unit
state
riskbenefit
approach
follow
countri
incid
rotaviru
sever
rotaviru
diseas
kill
infant
around
world
year
mainli
lowand
middleincom
countri
rotaviru
vaccin
becam
avail
diseas
blame
hospit
sever
dozen
death
per
year
unit
state
thu
usag
contamin
rotarix
may
justifi
benefit
vaccin
outweigh
concern
due
contamin
besid
rotarix
vaccin
anoth
vaccin
rotaviru
found
contamin
dna
fragment
simian
retroviru
srv
reveal
rotateq
vaccin
genet
engin
product
merck
rotateq
contain
five
humanbovin
reassort
strain
rotaviru
creat
children
hospit
pennsylvania
chop
rotaviru
strain
caus
bovin
diarrhoea
combin
human
strain
rotaviru
reassort
virus
transport
merck
master
seed
produc
use
african
green
monkey
kidney
cell
cultur
foetal
bovin
serum
porcin
trypsin
also
ad
produc
seed
stock
small
amount
residu
bovin
serum
cell
cultur
media
also
reveal
rotateq
vaccin
signific
silent
presenc
potenti
contamin
vaccin
fulli
estim
base
avail
data
present
howev
artifici
introduct
certain
agent
new
host
may
caus
complic
virolog
situat
clearli
underlin
exampl
vaccin
pig
contamin
circoviru
may
play
role
onset
spread
postwean
multisystem
wast
syndrom
pmw
inactiv
vaccin
produc
sheep
brain
protect
sheep
loup
ill
brain
inflammatori
ailment
spread
tick
clear
relat
escal
transmiss
scrapi
cell
cultur
central
way
viral
detect
facilit
downstream
analysi
laboratori
method
includ
electronmicroscopi
em
serolog
pcr
detect
antibodi
induc
certain
agent
host
also
convent
approach
convent
detect
method
serious
hamper
fact
mani
potenti
ea
replic
cell
cultur
suitabl
anim
model
identifi
howev
discoveri
unknown
noncultiv
virus
ongo
sever
method
use
identif
unknown
noncultiv
agent
em
em
combin
serolog
immun
serum
screen
peptid
express
librari
gener
sampl
infect
unknown
virus
nucleic
acid
base
detect
method
sensit
detect
small
number
virus
may
occur
absenc
diseas
limit
method
need
priori
knowledg
viral
nucleic
acid
sequenc
detect
moreov
interpret
pcr
posit
result
also
complex
often
requir
test
consid
fact
molecular
techniqu
like
pcr
detect
nucleic
acid
infect
rnasednas
digest
prior
pcr
improv
sensit
detect
remov
background
dna
nucleic
acid
virion
protect
dnasernas
obtain
pcr
posit
profoundli
indic
presenc
intact
perhap
infect
virion
may
help
address
question
noninfect
genom
fragment
nativ
virion
detect
pcr
besid
tradit
pcr
mani
variant
realtim
pcr
assay
develop
method
highli
vari
chemistri
use
eg
taqman
molecular
beacon
mb
scorpion
primer
dual
probe
system
dyelabel
oligonucleotid
ligat
primerprob
energi
transfer
system
priproet
compar
tradit
pcr
realtim
assay
faster
nearli
equal
sensit
allow
quantif
throughput
higher
risk
contamin
lower
need
open
test
tube
postpcr
handl
product
realtim
pcr
allow
autom
multiplex
probe
label
number
differ
fluorophor
lead
lower
diagnost
cost
final
consequ
veterinari
field
realtim
pcr
take
tradit
pcr
priproet
suggest
robust
diagnost
potenti
among
other
realtim
pcr
variant
priproet
need
shorter
conserv
region
hybridis
less
fragil
singl
point
mutat
socal
proxim
ligat
offer
novel
mean
detect
antibodi
nucleic
acid
amplif
method
antibodi
recognis
viral
bacteri
surfac
protein
bound
dna
strand
dna
strand
ligat
subsequ
amplifi
realtim
pcr
antibodi
bound
surfac
antigen
infecti
agent
consid
differ
type
pcr
common
featur
interpret
pcr
result
difficult
risk
assess
point
view
instanc
lower
risk
may
pose
contamin
nonspecif
speci
target
contamin
vaccin
howev
possibl
crossspeci
contamin
may
undermin
simplic
approach
case
bovin
spongiform
enceph
shown
abl
cross
speci
barrier
bovin
human
use
recent
technic
develop
includ
sequenceindepend
molecular
techniqu
combin
highthroughput
sequenc
microarray
analysi
may
improv
acceler
viral
discoveri
rotarix
srv
rotateq
reveal
massiv
parallel
sequenc
mp
combin
sequenceindepend
nucleic
acid
techniqu
microarray
test
rnasednas
digest
sampl
random
pcr
combin
mp
microarray
test
advantag
detect
much
wider
rang
potenti
extran
agent
current
mandat
method
like
cell
cultur
agentspecif
pcr
strength
metagenom
method
target
specif
viruspathogen
gener
capac
detect
wide
rang
infecti
agent
includ
unknown
emerg
novel
virus
advantag
microarray
potenti
highli
multiplex
detect
ea
numer
microb
simultan
detect
microarray
use
nucleotid
long
probe
provid
melt
temperatur
high
enough
ensur
hybridis
despit
restrict
complementari
probe
target
nevertheless
metagenom
microarray
test
limit
pcr
sensit
either
metagenom
microarray
screen
specif
virus
without
preamplif
clinic
sampl
microarray
sensit
enough
use
random
pcr
step
prior
microarray
hybridis
improv
sensit
microarray
enabl
time
detect
ea
without
priori
knowledg
infecti
agent
consid
fact
pcrbase
random
amplif
whole
genom
demonstr
gener
incomplet
coverag
genom
erlandsson
et
al
use
isotherm
multipl
displac
amplif
whole
genom
polymeras
polymeras
allow
good
coverag
genom
high
process
extrem
low
error
rate
polymeras
also
use
improv
sensit
agentspecif
realtim
pcr
socal
amppcr
unbias
random
preamplif
carri
specif
realtim
pcr
reaction
thu
amppcr
increas
specif
pcr
signal
allow
detect
posit
sampl
normal
detect
limit
specif
realtim
pcr
amppcr
reaction
take
place
one
vessel
risk
contamin
elimin
nest
pcr
replac
amppcr
situat
increas
sensit
need
eg
routin
pcr
diagnost
analysi
altogeth
use
metagenom
microarray
may
offer
new
perspect
vaccin
qualiti
control
allow
detect
probabl
present
agent
vaccin
without
priori
genet
knowledg
agent
priori
suspicion
contamin
ensur
viral
safeti
anim
human
medicin
product
regul
guidelin
develop
describ
potenti
agent
must
test
manufactur
vaccin
offici
list
ea
compil
ph
eur
see
chapter
relev
guidelin
issu
committe
medicin
product
veterinari
use
cvmp
advent
molecular
biolog
increas
globalis
veterinari
vaccin
product
altogeth
increas
need
review
progress
requir
viral
safeti
led
chang
regulatori
approach
present
guidelin
specif
recommend
extran
agent
test
veterinari
medicin
product
issu
mention
bodi
requir
start
materi
final
product
produc
vivo
vitro
must
test
presenc
potenti
contamin
includ
virus
bacteria
fungi
mycoplasma
addit
stabil
ident
appropri
ea
list
would
need
regular
revis
base
recent
epizoolog
data
eu
us
side
includ
specif
avian
puriti
test
describ
ph
eur
specif
subtypessubstrain
possibl
thorough
risk
assess
togeth
definit
level
contamin
despit
effort
manufactur
compet
author
risk
contamin
complet
exclud
probabl
minimis
pose
question
done
increas
maximum
safeti
regular
revis
test
work
seed
virus
wsv
batchesfinish
product
necessari
gmp
glp
level
inform
collect
geograph
locat
facil
qualiti
facilitieslaboratori
qualiti
health
statu
personnel
consolid
data
epidemiolog
monitor
concern
statu
epizooticenzoot
diseas
geograph
origin
start
materi
lead
reduct
number
ea
test
within
product
process
furthermor
would
essenti
defin
step
manufactur
process
molecular
method
appli
reduct
number
ea
increas
use
molecular
method
instead
tradit
anim
test
profound
concord
rule
reduc
refin
replac
anim
test
manufactur
test
veterinari
medicin
product
also
recognis
ph
eur
see
chapter
ph
eur
alreadi
allow
use
nucleic
acid
techniqu
provid
techniqu
offer
compar
sensit
specif
convent
method
see
chapter
new
method
may
assess
comparison
convent
compendi
method
rather
light
current
need
reach
latter
aim
valid
test
method
collabor
studi
involv
offici
medicin
control
laboratori
omcl
would
also
necessari
omcl
key
player
control
immunolog
pharmaceut
product
signific
base
neutral
statu
omcl
belong
nation
compet
author
avoid
contamin
cell
cultur
retrovirus
would
advis
includ
productenhanc
revers
transcriptas
assay
pert
ph
eur
cell
bank
test
explicit
indic
posit
test
result
investig
signific
pert
demonstr
low
level
revers
transcriptas
rt
activ
found
attenu
vaccin
chickencel
origin
subsequ
investig
reveal
detect
rt
activ
associ
presenc
incomplet
endogen
avian
retroviru
avian
leukosi
viru
howev
virus
prove
noninfecti
viral
envelop
protein
requir
fro
viral
infect
miss
presenc
vaccin
trigger
concern
regard
safeti
vaccin
event
point
pert
similarli
pcr
offer
extrem
increas
sensit
compar
tradit
method
biolog
signific
find
rais
question
rt
activ
may
conceiv
associ
sever
sourc
includ
cellular
enzym
like
dna
rna
polymeras
telomeras
cellular
element
like
retrotransposon
revis
develop
inactiv
method
start
materi
anim
origin
establish
well
control
test
system
insect
cell
line
insect
virus
also
profound
signific
signific
silent
presenc
potenti
contamin
vaccin
fulli
estim
artifici
introduct
agent
new
host
may
caus
complic
virolog
situat
instanc
vaccin
pig
contamin
may
contribut
occurr
postwean
multisystem
wast
syndrom
pmw
inactiv
vaccin
produc
sheep
brain
protect
sheep
loup
ill
brain
inflammatori
ailment
spread
tick
clearli
play
signific
role
escal
transmiss
scrapi
minimis
risk
ensur
high
qualiti
safe
vaccin
profound
import
stateofart
molecular
method
like
metagenom
microarray
improv
capac
manufactur
compet
author
reveal
contamin
identifi
wellknown
potenti
new
ea
implement
method
routin
test
vaccin
accept
ph
eur
ema
offici
method
need
valid
requir
accept
improv
interpret
result
obtain
test
especi
comparison
obtain
current
mandat
test
past
exampl
underlin
improv
abil
screen
vaccin
contamin
direct
relat
improv
vaccin
qualiti
safeti
subsequ
reveal
vaccin
manufactur
request
control
author
test
presenc
led
full
clearanc
vaccin
batch
releas
contamin
may
compromis
advantag
effect
veterinari
human
vaccin
may
undermin
trust
vaccin
vaccin
mainten
trust
profound
respons
manufactur
compet
author
